Browse

Lore Gruenbaum, PhD, discusses the direction mantle cell lymphoma is headed in addition to other critical areas of unmet needs.

The British biotechnology startup is making "pan-gamma delta” T cell engagers it says can address the limitations of similar, existing therapies.

The new data could support a broader approval submission for a therapy that is already under review and set to be showcased at the year’s biggest meeting for cancer research.